Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B2 | P80365 | 7/20 | 0.81 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | APEX1 | P27695 | 1/20 | 0.81 |
| ▸ | CES2 | O00748 | 2/20 | 0.75 |
| ▸ | CES1 | P23141 | 2/20 | 0.75 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20160598 | 1.00 | HSD11B2 (0.81) | HSD11B2HSD11B1POLBMAPTAPEX1 | |
| SCHEMBL422925 | 0.90 | HSD11B2 (0.77) | HSD11B2HSD11B1POLBMAPTAPEX1 | |
| SCHEMBL420853 | 0.90 | HSD11B1 (1.00) | HSD11B2HSD11B1POLBMAPTAPEX1 | |
| SCHEMBL13056500 | 0.90 | HSD11B1 (1.00) | HSD11B2HSD11B1POLBMAPTAPEX1 | |
| SCHEMBL18348593 | 0.90 | HSD11B1 (1.00) | HSD11B2HSD11B1POLBMAPTAPEX1 | |
| SCHEMBL11186600 | 0.90 | HSD11B1 (1.00) | HSD11B2HSD11B1POLBMAPTAPEX1 | |
| SCHEMBL420854 | 0.90 | HSD11B1 (1.00) | HSD11B2HSD11B1POLBMAPTAPEX1 | |
| SCHEMBL1721435 | 0.90 | HSD11B1 (1.00) | HSD11B2HSD11B1POLBMAPTAPEX1 | |
| SCHEMBL11186596 | 0.90 | HSD11B1 (1.00) | HSD11B2HSD11B1POLBMAPTAPEX1 | |
| SCHEMBL1721438 | 0.90 | HSD11B1 (1.00) | HSD11B2HSD11B1POLBMAPTAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3539974-B1 | METHOD FOR MODIFYING T CELL POPULATION | UNIV OSAKA (JP) | 2023-03-29 | — | — | EP | disclosed |
| US-20190284228-A1 | METHOD FOR MODIFYING T CELL POPULATION | OSAKA UNIVERSITY (JP) | 2019-09-19 | — | — | US | disclosed |
| EP-3539974-A1 | METHOD FOR MODIFYING T CELL POPULATION | Osaka University (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-9796751-B2 | Glycyrrhetinic acid derivative and use thereof | INI CORPORATION (JP) | 2017-10-24 | — | — | US | disclosed |
| US-9796751-B2 | Glycyrrhetinic acid derivative and use thereof | INI CORPORATION (JP) | 2017-10-24 | — | — | US | disclosed |
| US-20160376303-A1 | GLYCYRRHETINIC ACID DERIVATIVE AND USE THEREOF | INI CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376303-A1 | GLYCYRRHETINIC ACID DERIVATIVE AND USE THEREOF | GRHPR, GYPA, GPBAR1 | HSD11B2 112/4885HSD11B1 160/4885POLB 4429/4885 |
| US-20190284228-A1 | METHOD FOR MODIFYING T CELL POPULATION | CD4, RARG, RARB | HSD11B2 190/4885HSD11B1 106/4885POLB 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.